Overview
In June 2016, the U.S. Food and Drug Administration issued a safety warning that excessive doses of the over-the-counter anti-diarrheal medication Imodium (loperamide) could cause severe cardiac events, including fainting, arrhythmia, and cardiac arrest. The warning raised significant product liability concerns for consumers across New Jersey who had used the medication in amounts beyond recommended dosages — particularly individuals self-medicating to manage opioid withdrawal symptoms.
The FDA’s Findings
On June 7, 2016, the FDA warned that loperamide, when taken in doses exceeding recommended levels, could lead to serious cardiac events requiring emergency medical attention. Since the drug’s introduction approximately forty years earlier, regulators had linked ten deaths exclusively to Imodium, along with 48 cases of serious heart complications. Over half of these cardiac cases had been reported since 2010.
The FDA connected the surge in high-dose usage to the nationwide opioid epidemic. As prescription opioids became harder to obtain, some addicts turned to loperamide — an opioid receptor agonist that crosses the blood-brain barrier poorly at normal doses but produces central nervous system effects at very high doses — as a readily available alternative to manage withdrawal.
Regulatory Response
Following the warning, manufacturers were required to update labeling to include clearer warnings about the cardiac risks of exceeding recommended dosages. For consumers who had already suffered harm, however, the label change offered little comfort.
Personal Injury Considerations in New Jersey
Under New Jersey’s product liability framework, pharmaceutical manufacturers have a duty to warn consumers of known risks associated with their products. The New Jersey Product Liability Act, N.J.S.A. 2A:58C-1 et seq., establishes the standards for failure-to-warn claims against drug manufacturers.
Proving that the Imodium labels should have included stronger warnings before June 2016 requires demonstrating that the manufacturer knew or should have known about the cardiac risks at high doses and failed to adequately communicate those risks. This analysis typically involves expert testimony, FDA adverse event reporting data, and internal company communications.
The New Jersey Supreme Court’s decision in Kemp v. Bayer Corp., 2017 WL 2772252 (N.J. 2017), addressed the standards for pharmaceutical warning claims in the state, emphasizing the importance of adequate risk communication to both physicians and consumers.
What Affected Consumers Should Consider
Individuals who experienced cardiac events after using high doses of Imodium may have questions about their legal rights. Under New Jersey’s statute of limitations, personal injury claims generally must be filed within two years of the date of injury or the date when the injury was reasonably discoverable. N.J.S.A. 2A:14-2. However, the specific timeline varies depending on the facts of each case.
Key Takeaways
- The FDA’s June 2016 warning linked high-dose Imodium to fatal cardiac events
- Overdose cases were connected to the opioid epidemic and self-medication for withdrawal
- Manufacturers faced updated labeling requirements following the warning
- New Jersey’s Product Liability Act governs failure-to-warn claims against drug makers
- The statute of limitations for personal injury claims in New Jersey is generally two years
Reviewed by Britt J. Simon, Esq., Managing Partner — Simon Law Group, LLC — May 2026
The content on this website is for general informational purposes only and is not intended as legal advice. Every case is different. You should consult with a qualified attorney before making any legal decisions. Contacting us through this website does not create an attorney-client relationship. Prior results do not guarantee a similar outcome.